Crinetics Pharmaceuticals, Inc.
CRNX
Classifica tra le azioni
#2243
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Prezzo delle azioni
$84.95
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$9.00B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
100.12%
Paese
US
Scambia Crinetics Pharmaceuticals, Inc. (CRNX)
Categoria
Healthcare
Utile per Crinetics Pharmaceuticals, Inc. (CRNX)
Utile nel Jun 2026 TTM: $-501.43M
Secondo gli ultimi rapporti finanziari di Crinetics Pharmaceuticals, Inc., gli utili attuali della società sono $-501.43M. Nel 2023, la società ha registrato un utile di $-214.53M, una diminuzione rispetto a agli utili del 2022, che erano di $-163.92M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Crinetics Pharmaceuticals, Inc. dal 2016 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -489.02% |
NL
|
